Tag: retinitis pigmentosa
IDT Australia secures $3.2M manufacturing contract for investigational eye therapy
ASX-listed IDT Australia Limited has been awarded a five-year contract valued at $3.2 million for the manufacture of NPI-001 tablets, an investigational treatment for retinitis pigmentosa (RP), a degenerative eye disease that can lead to vision loss.
Featured Article
Driving the future of smart energy: GridBeyond and ABB unveil new white paper on battery storage innovation
As industries adopt cleaner, more intelligent energy solutions, the ability to manage, store, and trade energy efficiently is increasingly vital to sustaining a competitive edge.
